Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-29
2011-03-29
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S023000, C514S053000, C514S034000, C514S078000, C536S017900, C536S004100, C536S053000
Reexamination Certificate
active
07915227
ABSTRACT:
Pharmaceutical formulations containing (i) an amphiphilic drug and (ii) a short-chain sphingolipid are described and provided herein along with methods of making and using same.
REFERENCES:
patent: 4416872 (1983-11-01), Alving et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5395619 (1995-03-01), Zalipsky et al.
patent: 5527528 (1996-06-01), Allen et al.
patent: 5800833 (1998-09-01), Hope et al.
patent: 5936076 (1999-08-01), Higa et al.
patent: 6054433 (2000-04-01), Elias et al.
patent: 2002/0119990 (2002-08-01), Madden
patent: 0 896 816 (1999-02-01), None
patent: 0 896 816 (1999-02-01), None
patent: 8-034746 (1996-02-01), None
patent: WO 88/01171 (1988-02-01), None
patent: WO 99/41266 (1999-08-01), None
patent: 02/02077 (2002-01-01), None
patent: WO 02/02077 (2002-01-01), None
Slotte et al. (Biochemistry (1993), 32(31), 7886-92) (Abstract sent).
Futerman et al.(Methods in Enzymology (1992), 209(Phospholipid Biosynth.), 437-46) (Abstract sent).
Abe et al. (European Journal of Biochemistry (1992), 210(3), 765-73).
Abraham SA, et al, 2002, “Formation of transition metal-doxorubicin complexes inside liposomes,”Biochim. Biophys. Acta., vol. 1565(1), pp. 41-54.
Bai J, et al, 1997, “Measurement of spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in lipid vesicles, ”Biochemistry, vol. 36, pp. 8840-8848.
Bligh EJ, et al, 1959, “A rapid method of total lipid extraction and purification,”Can. J. Biochem. Physiol., vol. 37, pp. 911-917.
Carmichael J, et al, 1987, “Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing,”Cancer Res., vol. 47, pp. 936-942.
Cheung BC, et al, 1998, “Loading of doxorubicin into liposomes by forming Mn2+-drug complexes,”Biochim. Biophys. Acta., vol. 1414(1-2), pp. 205-216.
Druckmann S, et al, 1989, “Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies,”Biochim. Biophys. Acta, vol. 980, pp. 381-384.
Everts M, et al, 2003, “In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium,”Pharm. Res., vol. 20, pp. 64-72.
Gabizon A, 2001, “Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy,”Cancer Inv., vol. 19, pp. 424-436.
Gabizon A, et al, 1996, “Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines,”J. Drug Target, vol. 3, pp. 391-398.
Ghidoni R, et al, 1999, “Use of sphingolipid analogs: benefits and risks,”Biochim. Biophys. Acta, vol. 1439, pp. 17-39.
Haran G, et al Y, 1993, “Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases,”Biochim. Biophys. Acta, vol. 1151, pp. 201-215.
Harasym TO, et al, 1997, “Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes,”Cancer Chemother. Pharmacol., vol. 40, pp. 309-317.
Heijn M, et al, 1999, “Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor,”Cancer Res., vol. 59, pp. 4458-4463.
Horowitz AT, et al, 1992, “In vitro cytotoxicity of liposome-encapsulated doxrubicin: dependence on liposome composition and drug release,”Biochim. Biophys. Acta, vol. 1109, pp. 203-209.
Jeckel D, et al, 1993, “Truncated ceramide analogs as probes for sphingolipid biosynthesis and transport,”Adv. Lipid Res., vol. 26, pp. 143-160.
Koning GA, et al, 1999, “Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells,”Br. J. Cancer, vol. 80, pp. 1718-1725.
Koning GA, et al, 2003, “Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer Cells. An in vitro comparison,”Pharm. Res., vol. 20, pp. 1249-1257.
Koning, G.A., et al, 2003, “Short-chain liposomal sphingolipids potentiate in vitro doxorubicin cytotoxicity by enhancing its cellualr influx,” Conference Abstract for Liposome Advances: Progress in Drug and Vaccine Delivery, Dec. 15-19, 2003, London, UK.
Lasic DD, et al, 1995, “Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery,”Biochim. Biophys. Acta., vol. 1239(2), pp. 145-156.
Lothstein L, et al, 2001, “Anthracyclin drug targeting: cytoplasmic versus nuclear—a fork in the road,”Drug Res. Updates, vol. 4, pp. 169-177.
Mabrey, S., et al, 1978, “High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines”, Biochem., vol. 17, pp. 2464-2468.
Martin, F.J., 1990, “Pharmaceutical Manufacturing of Liposomes”,Specialized Drug Delivery Systems—Manufacturing and Production Technology, pp. 267-316.
Mayer, L.D., et al, 1986, “Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient”,Biochim. Biophys. Acta, vol. 857, pp. 123-126.
Mayer, L.D., et al., 1989, “Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in Mice”,Cancer Res., vol. 49, pp. 5922-5930.
Olson, F., et al, 1979, “Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes”,Biochim. Biophys. Acta, vol. 557, pp. 9-23.
Pan, XQ, et al, 2003, “Antitumor activity of folate receptor-targeted liposomal doxorubcin in a KB oral carcinoma murine xenograft model,”Pharm. Res., vol. 20, pp. 417-422.
Park, JW, et al, 2002, “Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery,”Clin. Cancer Res., vol. 8, pp. 1172-1181.
Robert J, et al, 1993, “Pharmacokinetics and metabolism of anthracyclines,” inCancer Surveys, vol. 17, pp. 219-252.
Rouser G, et al, 1970, “Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots,”Lipids, vol. 5, pp. 494-496.
Sillence, D.J., et al., 2000, “Assay for the transbilayer distribution of glycolipids: selective oxidation of glucosylceramide to glucuronylceramide by TEMPO nitroxyl radicals”,Journal of Lipid Research, vol. 41, pp. 1252-1260.
Smith PK, et al, 1985, “Measurement of protein using bicinchoninic acid,”Anal. Chem., vol. 150, pp. 76-85.
Speth PA, et al, 1988, “In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells,”Eur. J. Cancer Clin. Oncol., vol. 24, pp. 667-674.
Storm G, et al, 1985, “The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation”,Biochim. Biophys. Acta, vol. 818, pp. 341-351.
Szoka, F., Jr., et al, 1980, “Comparative properties and methods of preparation of lipid vesicles (liposomes)”,Ann. Rev. Biophys. Biogen., vol. 9, p. 457.
Tardi PG, et al, 1996, “Liposomal doxorubicin,”J. Drug Target, vol. 4, pp. 129-140.
Tsong, T.Y., 1975, “Effect of phase transition on the kinetics of dye transport in phospholipid bilayer structures”,Biochem., vol. 14, pp. 5409-5414; pp. 5415-5417.
Tubaro, E., et al, 1995, “Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models,”European Journal of Pharrnacology, vol. 294, pp. 555-563.
Uster PS, et al, 1996, “Insertion of poly(ethylene glycol) derivatized phospholipid into pre-fromed liposomes results in prolonged in vivo circulation time,”FEBS Lett., vol. 386, pp. 243-246.
Vaage J, et al,
Koning Gerben A.
Van Blitterswijk Wim J.
Veldman Robert J.
Verheij Marcel
Henry Michael C
Het Nederlands Kanker Instituut
Jiang Shaojia Anna
Nixon & Vanderhye P.C.
LandOfFree
Pharmaceutical formulations employing short-chain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations employing short-chain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations employing short-chain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658057